159 related articles for article (PubMed ID: 23730265)
41. Estimation of the Frequency of Intravenous Drug Users in Hamadan City, Iran, Using the Capture-recapture Method.
Khazaei S; Poorolajal J; Mahjub H; Esmailnasab N; Mirzaei M
Epidemiol Health; 2012; 34():e2012006. PubMed ID: 23173080
[TBL] [Abstract][Full Text] [Related]
42. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.
Turner KM; Hutchinson S; Vickerman P; Hope V; Craine N; Palmateer N; May M; Taylor A; De Angelis D; Cameron S; Parry J; Lyons M; Goldberg D; Allen E; Hickman M
Addiction; 2011 Nov; 106(11):1978-88. PubMed ID: 21615585
[TBL] [Abstract][Full Text] [Related]
43. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
[No Abstract] [Full Text] [Related]
44. Hepatitis C virus (HCV) infection & risk factors for HCV positivity in injecting & non-injecting drug users attending a de-addiction centre in northern India.
Basu D; Sharma AK; Gupta S; Nebhinani N; Kumar V
Indian J Med Res; 2015 Sep; 142(3):311-6. PubMed ID: 26458347
[TBL] [Abstract][Full Text] [Related]
45. Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan.
Todd CS; Nasir A; Stanekzai MR; Fiekert K; Sipsma HL; Vlahov D; Strathdee SA
Harm Reduct J; 2015 Oct; 12():22. PubMed ID: 26472126
[TBL] [Abstract][Full Text] [Related]
46. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high.
Goldberg D; Cameron S; McMenamin J
Commun Dis Public Health; 1998 Jun; 1(2):95-7. PubMed ID: 9644121
[TBL] [Abstract][Full Text] [Related]
47. Predictors of mortality among injecting and non-injecting HIV-negative drug users in northern Thailand.
Quan VM; Vongchak T; Jittiwutikarn J; Kawichai S; Srirak N; Wiboonnatakul K; Razak MH; Suriyanon V; Celentano DD
Addiction; 2007 Mar; 102(3):441-6. PubMed ID: 17298652
[TBL] [Abstract][Full Text] [Related]
48. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
Bird SM; Goldberg DJ; Hutchinson SJ
J Epidemiol Biostat; 2001; 6(3):243-65; discussion 279-85. PubMed ID: 11437088
[TBL] [Abstract][Full Text] [Related]
49. Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics.
Balogun MA; Murphy N; Nunn S; Grant A; Andrews NJ; Teo CG; Ramsay ME; Parry JV
Epidemiol Infect; 2009 Jul; 137(7):980-7. PubMed ID: 19102796
[TBL] [Abstract][Full Text] [Related]
50. Use of monitored CD4 cell counts: predictions of the AIDS epidemic in Scotland: CD4 Collaborative Group.
AIDS; 1992 Feb; 6(2):213-22. PubMed ID: 1348418
[TBL] [Abstract][Full Text] [Related]
51. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study.
Vickerman P; Hickman M; Judd A
Int J Epidemiol; 2007 Apr; 36(2):396-405. PubMed ID: 17218325
[TBL] [Abstract][Full Text] [Related]
52. Mortality of those who attended drug services in Scotland 1996-2006: record-linkage study.
Merrall EL; Bird SM; Hutchinson SJ
Int J Drug Policy; 2012 Jan; 23(1):24-32. PubMed ID: 21719267
[TBL] [Abstract][Full Text] [Related]
53. Current Burden of Hepatitis C Virus Infection Among Injecting Drug Users: A Mini Systematic Review of Prevalence Studies.
Rafiq SM; Banik GR; Khan S; Rashid H; Khandaker G
Infect Disord Drug Targets; 2014; 14(2):93-100. PubMed ID: 25313101
[TBL] [Abstract][Full Text] [Related]
54. Modelling and calibration of the hepatitis C epidemic in Australia.
Razali K; Amin J; Dore GJ; Law MG; HCV Projections Working Group
Stat Methods Med Res; 2009 Jun; 18(3):253-70. PubMed ID: 19036911
[TBL] [Abstract][Full Text] [Related]
55. Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002.
Brady JE; Friedman SR; Cooper HL; Flom PL; Tempalski B; Gostnell K
J Urban Health; 2008 May; 85(3):323-51. PubMed ID: 18344002
[TBL] [Abstract][Full Text] [Related]
56. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users.
Miller CL; Johnston C; Spittal PM; Li K; Laliberté N; Montaner JS; Schechter MT
Hepatology; 2002 Sep; 36(3):737-42. PubMed ID: 12198668
[TBL] [Abstract][Full Text] [Related]
57. Pre-AIDS mortality in the Edinburgh City Hospital HIV cohort.
Seaman SR; Brettle RP; Gore SM
Stat Med; 1997 Nov; 16(21):2459-74. PubMed ID: 9364654
[TBL] [Abstract][Full Text] [Related]
58. The association between alcohol use and hepatitis C status among injecting drug users in Glasgow.
O'Leary MC; Hutchinson SJ; Allen E; Palmateer N; Cameron S; Taylor A; Goldberg DJ
Drug Alcohol Depend; 2012 Jun; 123(1-3):180-9. PubMed ID: 22137645
[TBL] [Abstract][Full Text] [Related]
59. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.
Dore GJ; Hellard M; Matthews GV; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan G; White P; French R; Rawlinson W; Lloyd AR; Kaldor JM;
Gastroenterology; 2010 Jan; 138(1):123-35.e1-2. PubMed ID: 19782085
[TBL] [Abstract][Full Text] [Related]
60. Epidemic of HIV coupled with hepatitis C virus among injecting drug users of Himalayan West Bengal, Eastern India, Bordering Nepal, Bhutan, and Bangladesh.
Sarkar K; Bal B; Mukherjee R; Chakraborty S; Niyogi SK; Saha MK; Bhattacharya SK
Subst Use Misuse; 2006; 41(3):341-52. PubMed ID: 16467010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
